WHAT IS CLAIMED IS:

1. Use of trofinetide for the manufacture of a medicament for treating Rett syndrome in a subject, wherein trofinetide is to be administered in a daily amount of:

a) 4-10.0 g if the subject weighs between 8-11.9 kg;

b) 10.1-14.0 g if the subject weighs between 12.0-20.0 kg;

c) 14.1-18.0 g if the subject weighs between 20.1-35.0 kg;

d) 18.1-22.0 g if the subject weighs between 35.1-50.0 kg; or

e) 22.1-26 g if the subject weighs between 50.1-150 kg.

2. The use of claim 1, wherein the administration of trofinetide results in an $AUC_{0\text{-}12,\ ss}$ of 755 µg•h/mL to 1300 µg•h/mL in the subject.

3. The use of claim 1 or claim 2, wherein the administration of trofinetide results in an $AUC_{0\text{-}12,\ ss}$ of at least 755 µg•h/mL, at least 780 µg•h/mL, at least 790 µg•h/mL, at least 800 µg•h/mL, at least 820 µg•h/mL, at least 840 µg•h/mL, at least 860 µg•h/mL, at least 880 µg•h/mL, at least 900 µg•h/mL, at least 920 µg•h/mL, at least 940 µg•h/mL, at least 960 µg•h/mL, at least 980 µg•h/mL, at least 1000 µg•h/mL, at least 1020 µg•h/mL, at least 1040 µg•h/mL, at least 1060 µg•h/mL, at least 1080 µg•h/mL, at least 1100 µg•h/mL, at least 1120 µg•h/mL, at least 1140 µg•h/mL, at least 1160 µg•h/mL, at least 1180 µg•h/mL, at least 1200 µg•h/mL, at least 1220 µg•h/mL, at least 1240 µg•h/mL, at least 1260 µg•h/mL, or at least 1280 µg•h/mL in the subject.

4. The use of any one of claims 1-3, wherein the administration of trofinetide to the subject results in a $C_{max,\ ss}$ of 100 to 200 µg/mL in the subject.

5. The use of any one of claims 1-4, wherein the administration of trofinetide to the subject results in a $C_{max,\ ss}$ of at least 100 µg/mL, at least 110 µg/mL, at least 120 µg/mL, at least 130 µg/mL, at least 140 µg/mL, at least 150 µg/mL, at least 160 µg/mL, at least 170 µg/mL, at least 180 µg/mL, at least 190 µg/mL, or at least 200 µg/mL in the subject.

6. The use of any one of claims 1-5, wherein trofinetide is to be administered to the subject in a single dose per day or in multiple doses per day that sum to the daily amount.

7. The use of claim 6, wherein trofinetide is to be administered to the subject in two doses per day that sum to the daily amount.

8. The use of any one of claims 1-7, wherein trofinetide is to be administered as a pharmaceutical composition comprising trofinetide and a pharmaceutically acceptable carrier.

9. The use of claim 8, wherein the pharmaceutically acceptable carrier comprises water and the pharmaceutical composition is a solution.

10. The use of claim 8, wherein the concentration of trofinetide in the solution is 0.05 g/mL – 0.7 g/mL in the solution or 0.2 g/mL in the solution.

11. The use of any one of claims 1-10, wherein trofinetide is to be orally administered to the subject.

12. The use of any one of claims 1-11, wherein the subject is human.

13. The use of claim 12, wherein the subject is female.

14. The use of any one of claims 1-13, wherein the subject is 18 months to 20 years old.

15. The use of any one of claims 1-14, wherein the subject has a MECP2 mutation.

16. The use of any one of claims 1-15, wherein the Rett syndrome is atypical Rett syndrome or classic/typical Rett syndrome.

17. The use according to any one of claims 1-16, wherein trofinetide is provided in the solution in an amount of 0.05 to 0.6 g/ml, 0.1 to 0.4 g/mL, or 0.15 to 0.3 g/mL.

18. The use according to any one of claims 1-17, wherein the amount of trofinetide is effective for providing an $AUC_{0\text{-}12,\ ss}$ of 755 μg•h/mL to 1300 μg•h/mL in the subject and/or a $C_{max,\ ss}$ of 100 to 200 μg/mL in the subject.

19. The use according to any one of claims 1-18, further comprising one or more excipients selected from a preservative, sweetener, flavoring agent, and coloring agent.